A Phase I Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2018
At a glance
- Drugs ONO 7475 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 31 Aug 2018 Biomarkers information updated
- 12 Jun 2018 Planned primary completion date changed from 10 May 2018 to 15 Jan 2019.
- 20 Sep 2017 Status changed from not yet recruiting to recruiting.